Highlights Shionogi & Co., Ltd.

Equities

4507

JP3347200002

Delayed Japan Exchange Other stock markets 02:00:00 2024-06-27 EDT			5-day change	1st Jan Change
6,256 ^JPY	+0.08%		+2.12%	-7.97%

06-25	Japanese Shares Close Higher as Officials Address Yen Volatility Concerns	MT
06-25	Shionogi & Co Introduces Covgoze Vaccine for Covid-19 in Japan	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Shionogi & Co Introduces Covgoze Vaccine for Covid-19 in Japan	06-24	MT
Shionogi & Co. to Dispose of 450 Million Yen Worth of Shares as Restricted Stock Compensation	06-21	MT
Japan's Nikkei drifts sideways as more earnings, US CPI awaited	05-13	RE
Japan's Shionogi says COVID treatment did not meet endpoint in late-stage trial	05-13	RE
Akili, Inc. Announces an Amendment to its Strategic Distribution Agreement with Shionogi & Co., Ltd	04-30	CI
Shionogi & Co., Ltd. Revises Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024	04-25	CI
Shionogi & Co Completes Cancellation of 10.84 Million Treasury Shares	04-19	MT
Shionogi & Co., Ltd. Announces New Data from the European Real-World Evidence Study of Fetroja®/F etcroja® (cefiderocol)	04-18	CI
Shionogi Completes Up to 75 Billion Yen Share Buyback	03-29	MT
Tranche Update on Shionogi & Co., Ltd.'s Equity Buyback Plan announced on July 31, 2023.	03-28	CI
Final dividend	03-27	FA
Shionogi & Co., Ltd.'s Equity Buyback announced on July 31, 2023, has closed with 10,842,100 shares, representing 3.73% for ¥74,999.22 million.	03-21	CI
Shionogi Buys Back Shares Worth Nearly 12 Billion Yen	03-06	MT
GSK says ViiV's cabotegravir study supports longer HIV dose interval	03-05	AN
Shionogi & Co., Ltd. Announces Xocova Obtains Standard Approval in Japan for the Treatment of SARS-CoV-2 Infection	03-05	CI
US urges court to preserve Obamacare mandate to cover cancer screenings, HIV drugs	03-04	RE
GSK's new HIV drug formula could support longer dosing intervals (March 4)	03-04	RE
GSK Says Data Show For First Time New Ultra Long-Acting Cabotegravir Formulation That Doubles Current Dosing Interval	03-04	RE
US court to weigh Obamacare mandate to cover HIV drug, cancer screenings	03-04	RE
PureTech notes positive results from Shionogi's EndeavorRx ADHD trial	02-27	AN

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Shionogi & Co., Ltd.

Equities

4507

JP3347200002

Highlights

Filters